Attitudes and practice patterns for maintaining relative dose intensity of chemotherapy in outpatient clinics: results of a Japanese web-based survey

Table 4 Management of subsequent cycles of chemotherapy after low-risk FN

		Group ML (n = 185)		Group BC (n = 160)
		Number	%	Number	%	P-value
Q. Dose of chemotherapy
	Dose reduction is not required	143	77	49	31	P < 0.001
	Dose reduction is required if febrile neutropenia was treated by intravenous antibiotics	18	10	56	35	P < 0.001
	Dose reduction is required at any rate	22	12	55	34	P < 0.001
	Other	2	1	0	0	P = 0.501
	Total	185	100	160	100
Q. Antibiotics
	Antimicrobial prophylaxis deserves consideration	67	36	42	26	P = 0.049
	Antibiotics are taken into account on the next episode of febrile neutropenia	91	49	95	59	P = 0.065
	I typically don’t administer antibiotics	27	15	23	14	P = 1
	Other	0	0	0	0	P = 1
	Total	185	100	160	100
Q. G-CSF
	G-CSF prophylaxis deserves consideration	47	25	26	16	P = 0.047
	G-CSF is taken into account when neutropenia occurs	114	62	75	47	P = 0.006
	G-CSF is taken into account on the next episode of febrile neutropenia	15	8	46	29	P < 0.001
	I typically don’t administer G-CSF	7	4	13	8	P = 0.107
	Other	2	1	0	0	P = 0.501
	Total	185	100	160	100

ISSN: 1471-2407